Physician profile
Christopher G Acker
NPI 1053319426
$1,844.69
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $48.07 · 2021: $22.11 · 2022: $1,202 · 2023: $192 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264 · Education: $39.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.16 |
| Education | $39.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,105.95 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $170.44 | 2019-2024 | Jynarque |
| Avenu Medical INC. | $122.77 | 2019 | |
| Akebia Therapeutics INC | $94.36 | 2019-2023 | Auryxia |
| Amgen INC. | $66.49 | 2021-2024 | Krystexxa |
| Travere Therapeutics, INC. | $45.86 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $45.83 | 2023-2024 | |
| Glaxosmithkline, LLC. | $37.57 | 2023 | Benlysta |
| Fresenius USA Marketing, INC. | $37.03 | 2022-2024 | Velphoro |
| Mallinckrodt Enterprises LLC | $34.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.87 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $14.09 | 2023 | Farxiga |
| Astellas Pharma US INC | $13.96 | 2023 | Myrbetriq |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.